Diamond Hill Capital Management LLC Investment Advisor Purchases New Position in Aurinia Pharmaceuticals Inc $AUPH

Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 92,212 shares of the biotechnology company’s stock, valued at approximately $1,565,000. Diamond Hill Capital Management LLC Investment Advisor owned approximately 0.07% of Aurinia Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Aurinia Pharmaceuticals by 65.3% during the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company’s stock worth $2,956,000 after buying an additional 145,179 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 8.7% in the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock worth $4,048,000 after acquiring an additional 40,380 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 3,497 shares in the last quarter. Creative Planning grew its position in Aurinia Pharmaceuticals by 21.0% during the 2nd quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 3,594 shares during the last quarter. Finally, Legal & General Group Plc grew its position in Aurinia Pharmaceuticals by 16.5% during the 2nd quarter. Legal & General Group Plc now owns 141,492 shares of the biotechnology company’s stock worth $1,201,000 after acquiring an additional 20,027 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AUPH. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Wall Street Zen cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. Finally, Royal Bank Of Canada raised their target price on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $17.67.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, CEO Kevin Tang acquired 343,620 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $15.28 per share, for a total transaction of $5,250,513.60. Following the completion of the acquisition, the chief executive officer directly owned 12,838,101 shares of the company’s stock, valued at approximately $196,166,183.28. This represents a 2.75% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 814,606 shares of company stock valued at $12,455,129 in the last quarter. Corporate insiders own 10.40% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH stock opened at $15.29 on Tuesday. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 6.68 and a beta of 1.42. Aurinia Pharmaceuticals Inc has a 12 month low of $10.34 and a 12 month high of $19.25. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07. The stock has a 50-day moving average price of $15.91 and a 200 day moving average price of $15.39.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. Research analysts expect that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.